本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ultragenyx Pharmaceutical Inc

19.38
-0.6200-3.10%
盤後19.30-0.0800-0.41%19:52 EDT
成交量:153.06萬
成交額:2,970.83萬
市值:18.70億
市盈率:-3.32
高:20.09
開:20.00
低:19.10
收:20.00
52周最高:42.37
52周最低:18.29
股本:9,647.76萬
流通股本:9,279.49萬
量比:0.55
換手率:1.65%
股息:- -
股息率:- -
每股收益(TTM):-5.8316
每股收益(LYR):-5.8316
淨資產收益率:-608.47%
總資產收益率:-22.03%
市淨率:-23.37
市盈率(LYR):-3.32

資料載入中...

2024/06/11

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/30

重要事件披露

Form 8-K - Current report
2024/05/18

SEC問詢函

Form CORRESP - Correspondence
2024/05/03

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/02

重要事件披露

Form 8-K - Current report
2024/04/15

重要事件披露

Form 8-K - Current report
2024/03/12

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/21

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/15

重要事件披露

Form 8-K - Current report
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/08

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/01/08

重要事件披露

Form 8-K - Current report
2023/12/29

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/12/22

重要事件披露

Form 8-K - Current report
2023/11/03

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/03

重要事件披露

Form 8-K - Current report